Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center
Advertisement
Articles by Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center
Advertisement
Latest Updated Articles
PI3KCA Inhibition: Managing AEs in HR+ mBCPublished: July 21st 2021 | Updated:
Early Stage HR+ Breast Cancer: Optimizing Multigene AssaysPublished: August 4th 2021 | Updated:
Using Genomic Assays for Early Stage HR+ Breast CancerPublished: July 28th 2021 | Updated:
ES HR+ Breast Cancer: CDK4/6 Inhibitors in Clinical PracticePublished: August 11th 2021 | Updated:
Emerging Agents for the Management of HR+ mBCPublished: July 28th 2021 | Updated:
Using CDK4/6 Inhibitors After HR+ mBC Disease ProgressionPublished: July 21st 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5